✦ LIBER ✦

0-35. Guiding systemic therapy in metastatic breast cancer by blood tumour markers

✍ Scribed by J.F.R. Robertson; S. Kramer; J.J. Syzmendera; C. Selby; R. Coleman; A. Howell; J. Winstanley; P.E. Jonssen; E. Bombardieri; R. Sainsbury; R.W. Blarney; H. Gronberg; E. Kumpulainen

Book ID: 114317041
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 142 KB
Volume: 6
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(97)90616-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The use of blood tumour markers in the m

The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy

✍ K.L. Cheung; A.J. Evans; J.F.R. Robertson 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 73 KB

The objective measurement of remission a

The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers

✍ J.F.R Robertson; W Jaeger; J.J Syzmendera; C Selby; R Coleman; A Howell; J Winst 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 102 KB

Pre-treatment serum levels of tumour mar

Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival

✍ K.V. Albuquerque; M.R. Price; R.A. Badley; I. Jonrup; D. Pearson; R.W. Blamey; J 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 409 KB

75. Myeloablative therapy supported by p

75. Myeloablative therapy supported by peripheral blood stem cells (PBSC) in poor prognosis metastatic breast cancer — a phase 1/11 study

✍ D.A. Cameron; L. Lee; J. MacKay; H. Gabra; J. Gardiner; J. Craig; A.C. Parker; R 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 153 KB

OC3.06.5 ROLE OF CIRCULATING TUMOUR MARK

OC3.06.5 ROLE OF CIRCULATING TUMOUR MARKER CA19.9 AND ANTIANGIOGENIC THERAPY WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER ON FIRST LINE SYSTEMIC TREATMENT

✍ G. Del Vecchio Blanco; V. Formica; I. Portarena; A. Caruso; E. Mannisi; M. Massa 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 76 KB

378 Taxol® (paclitaxel) 225 mg/m2 b

378 Taxol® (paclitaxel) 225 mg/m2 by 3-hour infusion without G-CSF as a second line therapy in patients (PTS) with metastatic breast cancer (MBC)

✍ Ph. Bougnoux; R. Delva; D. Serin; M. Namer; G. Piot; J.P. Lotz; J.F. Ramée; E. V 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 170 KB